Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study

MLA

Peter Reichardt, et al. “Long-Term Efficacy of Denosumab in Giant Cell Tumor of Bone: Results of an Open-Label Phase 2 Study.” Annals of Oncology, vol. 28, Sept. 2017, pp. v645–46. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7abf6549e5dcb4887864fc986faa0e43&authtype=sso&custid=ns315887.

APA

Peter Reichardt, Shanta Chawla, A. Le Cesne, Emanuela Palmerini, Hans Gelderblom, Robert J. Grimer, J-Y. Blay, Piotr Rutkowski, Amy Feng, & Danielle Jandial. (2017). Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. Annals of Oncology, 28, v645–v646.

Chicago

Peter Reichardt, Shanta Chawla, A. Le Cesne, Emanuela Palmerini, Hans Gelderblom, Robert J. Grimer, J-Y. Blay, Piotr Rutkowski, Amy Feng, and Danielle Jandial. 2017. “Long-Term Efficacy of Denosumab in Giant Cell Tumor of Bone: Results of an Open-Label Phase 2 Study.” Annals of Oncology 28 (September): v645–46. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7abf6549e5dcb4887864fc986faa0e43&authtype=sso&custid=ns315887.